This company has been marked as potentially delisted and may not be actively trading. NASDAQ:APTO Aptose Biosciences (APTO) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisHeadlinesInsider TradesTrendsBuy This Stock About Aptose Biosciences Stock (NASDAQ:APTO) Get Aptose Biosciences alerts:Sign Up Key Stats Today's Range$1.71▼$1.7150-Day Range$1.71▼$6.8652-Week Range$1.35▼$50.10VolumeN/AAverage Volume227,964 shsMarket Capitalization$3.66 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada. Read More Receive APTO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. APTO Stock News HeadlinesAptose Biosciences Announces Completion of Acquisition by Hanmi PharmaceuticalJune 30, 2026 | financialpost.comFAptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral PresentationJune 15, 2026 | globenewswire.comThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.August 21 at 1:00 AM | Reagan Gold Group (Ad)Aptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi PharmaceuticalMay 29, 2026 | financialpost.comFAptose Reports First Quarter 2026 ResultsMay 13, 2026 | financialpost.comFAptose Reports First Quarter 2026 ResultsMay 13, 2026 | globenewswire.comAptose Biosciences Announces Update on Anticipated Timing of Closing of the Plan of Arrangement with Hanmi PharmaceuticalApril 30, 2026 | markets.businessinsider.comAptose Hanmi Acquisition Closing Delayed Pending Korean ApprovalsApril 30, 2026 | tipranks.comSee More Headlines APTO Stock Analysis - Frequently Asked Questions How were Aptose Biosciences' earnings last quarter? Aptose Biosciences Inc. (NASDAQ:APTO) posted its quarterly earnings data on Thursday, August, 8th. The biotechnology company reported ($12.90) EPS for the quarter, topping analysts' consensus estimates of ($17.40) by $4.50. When did Aptose Biosciences' stock split? Shares of Aptose Biosciences reverse split before market open on Wednesday, February 26th 2025.The 1-30 reverse split was announced on Tuesday, February 18th 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Aptose Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aptose Biosciences investors own include Digital Turbine (APPS), Okta (OKTA), Canoo (GOEV), CrowdStrike (CRWD) and NVIDIA (NVDA). Company Calendar Last Earnings8/08/2024Today8/21/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:APTO CIK882361 Webwww.aptose.com Phone858-926-2730Fax905-234-2120Employees31Year Founded2014Profitability EPS (Trailing Twelve Months)($89.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$51.21 million Net MarginsN/A Pretax MarginN/A Return on Equity-5,683.22% Return on Assets-300.44% Debt Debt-to-Equity RatioN/A Current Ratio1.05 Quick Ratio1.05 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.19) per share Price / Book-9.00Miscellaneous Outstanding Shares2,141,000Free Float63,446,000Market Cap$3.66 million OptionableNo Data Beta1.04 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:APTO) was last updated on 8/21/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptose Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptose Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
